Stem cell biology has emerged as a pillar of regenerative medicine and translational research, transforming how scientists and clinicians understand human health and disease. The regenerative potential of pluripotent embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) have offered not only new avenues of therapeutic avenues but also new platforms for researching disease modelling, drug screening, and precision medicine uses. With scientific revolutions based on CRISPR-Cas9-mediated genome editing, patient-derived induced pluripotent stem cell lines, 3-dimentional organoid culture systems, nanotechnology-based cellular engineering, and enhanced techniques in bioprinting, the prospect of stem cell biology could ultimately translate from bench to bedside along to provide clinical intervention for diseases. These advancements are particularly complex and focus on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, cardiovascular disease, diabetes, ophthalmic degenerations and many types of cancer. At the same time, and equally important, is the ever-increasing numbers of scientific publications corresponding to significant progress and global interests in stem cell investigation; but, while progress exists, ethical issues, immune compatibility, scale of production and long-term safety must be addressed before stem cell therapy can be utilized for clinical use. The field is currently at a significant intersection where scientific capacity must meet ethical integrity, technical feasibility and regulatory feasibility to facilitate stem cell-based interventions to deliver improvements to modern medicine.
V Verma (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: